SPECIAL FEATURES

Highlights of This Issue 3231

CCR Translations

3233 Biomarker Discovery from We to Me: Is Learningfrom Each Patient a New Approach?Stephanie LheureuxSee related article, p. 3282

3236 The Long Neglected Player: Modeling TumorUptake to Guide Optimal DosingLeire Ruiz-Cerd�a, Eduardo Asín-Prieto,Zinnia P. Parra-Guillen, and I~naki F. Troc�onizSee related article, p. 3325

3239 Antigen Presentation Keeps Trending inImmunotherapy ResistanceAnusha Kalbasi and Antoni RibasSee related article, p. 3366

CCR Drug Updates

3242 FDA Approval: Gemtuzumab Ozogamicin for theTreatment of Adults with Newly DiagnosedCD33-Positive Acute Myeloid LeukemiaEmily Y. Jen, Chia-Wen Ko, Jee Eun Lee, Pedro L. Del Valle,Antonina Aydanian, Charles Jewell, Kelly J. Norsworthy,Donna Przepiorka, Lei Nie, Jiang Liu, ChristopherM. Sheth,Marjorie Shapiro, Ann T. Farrell, and Richard Pazdur

CLINICAL TRIAL BRIEF REPORT

3247 Prospective Clinical Trial of Ixazomib,Dexamethasone, and Rituximab as PrimaryTherapy in Waldenstr€om MacroglobulinemiaJorge J. Castillo, Kirsten Meid, Joshua N. Gustine,Toni Dubeau, Patricia Severns, Zachary R. Hunter,Guang Yang, Lian Xu, and Steven P. Treon

CLINICAL TRIALS: TARGETED THERAPY

3253 A First-in-Human Phase 1 Study of LY3023414,an Oral PI3K/mTOR Dual Inhibitor, in Patientswith Advanced CancerJohanna C. Bendell, Anna M. Varghese, David M. Hyman,Todd M. Bauer, Shubham Pant, Sophie Callies, Ji Lin,Ricardo Martinez, Enaksha Wickremsinhe, Aaron Fink,Volker Wacheck, and Kathleen N. Moore

3263 Evaluation of Prexasertib, a Checkpoint Kinase1 Inhibitor, in a Phase Ib Study of Patients withSquamous Cell CarcinomaDavid S. Hong, Kathleen Moore, Manish Patel,Stefan C. Grant, Howard A. Burris III, WilliamN.William Jr,Suzanne Jones, Funda Meric-Bernstam, Jeffrey Infante,Lisa Golden, Wei Zhang, Ricardo Martinez,Sameera Wijayawardana, Richard Beckmann,Aimee Bence Lin, Cathy Eng, and Johanna Bendell

3273 Complete and Durable Responses in PrimaryCentral Nervous System PosttransplantLymphoproliferative Disorder with Zidovudine,Ganciclovir, Rituximab, and DexamethasoneJames P. Dugan, Bradley M. Haverkos, Lynda Villagomez,Ludmila K. Martin, Mark Lustberg, John Patton,Marisa Martin, Ying Huang, Gerard Nuovo, Fengting Yan,Robert Cavaliere, Joyce Fingeroth, Shannon C. Kenney,Richard F. Ambinder, Gerard Lozanski, Pierluigi Porcu,Michael A. Caligiuri, and Robert A. Baiocchi

CLINICAL TRIALS: IMMUNOTHERAPY

3282 Exceptional Response to Pembrolizumab in aMetastatic, Chemotherapy/Radiation-ResistantOvarian Cancer Patient Harboring a PD-L1-Genetic RearrangementStefania Bellone, Natalia Buza, Jungmin Choi,Luca Zammataro, Laurie Gay, Julia Elvin, David L. Rimm,Yuting Liu, Elena S. Ratner, Peter E. Schwartz, andAlessandro D. SantinSee related commentary, p. 3233

3292 A Model of Overall Survival Predicts TreatmentOutcomes with Atezolizumab versusChemotherapy in Non–Small Cell Lung CancerBased on Early Tumor KineticsLaurent Claret, Jin Y. Jin, Charles Fert�e, Helen Winter,Sandhya Girish, Mark Stroh, Pei He, Marcus Ballinger,Alan Sandler, Amita Joshi, Achim Rittmeyer,David Gandara, Jean-Charles Soria, and Ren�e Bruno

July 15, 2018 � Volume 24 � Number 14

Clinical Cancer Research

Table ofContents

iv

on May 6, 2019. © 2018 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from

PRECISION MEDICINE AND IMAGING

3299 Prevalent Homozygous Deletions of Type IInterferon and Defensin Genes in Human CancersAssociate with Immunotherapy ResistanceZhenqing Ye, Haidong Dong, Ying Li, Tao Ma,Haojie Huang, Hon Sing Leong, Jeanette Eckel-Passow,Jean-Pierre A. Kocher, Han Liang, and Liguo Wang

3309 A Gallium-67/68–Labeled Antibody Fragmentfor Immuno-SPECT/PET Shows Low RenalRadioactivity Without Loss of Tumor UptakeTomoya Uehara, Miki Yokoyama, Hiroyuki Suzuki,Hirofumi Hanaoka, and Yasushi Arano

3317 Cell-Free DNA Modification Dynamics inAbiraterone Acetate-Treated Prostate CancerPatientsJuozas Gordevi�cius, Algimantas Kriš�ci�unas,Daniel E. Groot, Steven M. Yip, Miki Susic, Andrew Kwan,Rafal Kustra, AnthonyM. Joshua, KimN. Chi, Art Petronis,and Gabriel Oh

3325 Prediction of the Optimal Dosing Regimen Usinga Mathematical Model of Tumor Uptake forImmunocytokine-Based Cancer ImmunotherapyBenjamin Ribba, Christophe Boetsch, Tapan Nayak,Hans Peter Grimm, Jehad Charo, Stefan Evers,Christian Klein, Jean Tessier, Jean Eric Charoin,Alex Phipps, Pavel Pisa, and Volker Teichgr€aberSee related commentary, p. 3236

3334 Resistance Mechanisms to Targeted Therapiesin ROS1þ and ALKþ Non–small Cell Lung CancerCaroline E. McCoach, Anh T. Le, Katherine Gowan,Kenneth Jones, Laura Schubert, Andrea Doak,Adriana Estrada-Bernal, Kurtis D. Davies,Daniel T. Merrick, Paul A. Bunn Jr, W. Tom Purcell,Rafal Dziadziuszko, Marileila Varella-Garcia,Dara L. Aisner, D. Ross Camidge, and Robert C. Doebele

3348 Change in Topoisomerase 1–Positive CirculatingTumor Cells Affects Overall Survival in Patientswith Advanced Breast Cancer after Treatment withEtirinotecan PegolHope S. Rugo, Javier Cortes, Ahmad Awada,Joyce O'Shaughnessy, Chris Twelves, Seock-Ah Im,Alison Hannah, Lin Lu, Sherwin Sy, Katie Caygill,Deborah A. Zajchowski, DarrenW. Davis, Mary Tagliaferri,Ute Hoch, and Edith A. Perez

3358 Risk Assessment after NeoadjuvantChemotherapy in Luminal Breast Cancer Using aClinicomolecular PredictorSibylle Loibl, Karsten Weber, Jens Huober,Kristin Krappmann, Frederik Marm�e, Christian Schem,Knut Engels, Berit Maria Pfitzner, Sherko K€ummel,Jenny Furlanetto, Arndt Hartmann, Silvia Darb-Esfahani,Volkmar M€uller, Annette Staebler, Gunter von Minckwitz,Ralf Kronenwett, and Carsten Denkert

TRANSLATIONAL CANCER MECHANISMSAND THERAPY

3366 The RNA-binding Protein MEX3B MediatesResistance to Cancer Immunotherapy byDownregulating HLA-A ExpressionLu Huang, Shruti Malu, Jodi A. McKenzie,Miles C. Andrews, Amjad H. Talukder, Trang Tieu,Tatiana Karpinets, Cara Haymaker, Marie-Andr�ee Forget,Leila J. Williams, Zhe Wang, Rina M. Mbofung,Zhi-Qiang Wang, Richard Eric Davis, Roger S. Lo,Jennifer A. Wargo, Michael A. Davies,Chantale Bernatchez, Timothy Heffernan,RodabeN. Amaria, Anil Korkut, Weiyi Peng, Jason Roszik,Gregory Liz�ee, Scott E. Woodman, and Patrick HwuSee related commentary, p. 3239

3377 BRAF and MEK Inhibitors Increase PD-1-PositiveMelanoma Cells Leading to a PotentialLymphocyte-Independent Synergism withAnti–PD-1 AntibodyMartina Sanlorenzo, Igor Vujic, Arianna Floris,Mauro Novelli, Loretta Gammaitoni, Lidia Giraudo,Marco Macagno, Valeria Leuci, Ramona Rotolo,Chiara Donini, Marco Basiric�o, Pietro Quaglino,Maria Teresa Fierro, Silvia Giordano, Maria Sibilia,Fabrizio Carnevale-Schianca, Massimo Aglietta, andDario Sangiolo

3386 Targeting the Leukemia Antigen PR1 withImmunotherapy for the Treatment of MultipleMyelomaGheath Alatrash, Alexander A. Perakis, Celine Kerros,Haley L. Peters, Pariya Sukhumalchandra, Mao Zhang,Haroon Jakher, Madhushree Zope, Rebecca Patenia,Anna Sergeeva, Shuhua Yi, Ken H. Young, Anne V. Philips,Amanda M. Cernosek, Haven R. Garber, Na Qiao,Jinsheng Weng, Lisa S. St John, Sijie Lu,Karen Clise-Dwyer, Elizabeth A. Mittendorf, QingMa, andJeffrey J. Molldrem

3397 Interferon-Stimulated Genes Are Involved inCross-resistance to Radiotherapy in Tamoxifen-Resistant Breast CancerAnnemarie E.M. Post, Marcel Smid, Anika Nagelkerke,John W.M. Martens, Johan Bussink, Fred C.G.J. Sweep,and Paul N. Span

3409 Combinatorial Effects of VEGFR Kinase InhibitorAxitinib and Oncolytic Virotherapy in Mouse andHuman Glioblastoma Stem-Like Cell ModelsDipongkor Saha, Hiroaki Wakimoto, Cole W. Peters,Slawomir J. Antoszczyk, Samuel D. Rabkin, andRobert L. Martuza

Table of Contents

v

on May 6, 2019. © 2018 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from

3423 Targeting NADþ/PARP DNA Repair Pathway as aNovel Therapeutic Approach to SDHB-MutatedCluster I Pheochromocytoma and ParagangliomaYing Pang, Yanxin Lu, Veronika Caisova, Yang Liu,Petra Bullova, Thanh-Truc Huynh, Yiqiang Zhou, Di Yu,Zdenek Frysak, Igor Hartmann, David Taïeb, Karel Pacak,and Chunzhang Yang

3433 Discovery of a Glucocorticoid Receptor (GR)Activity Signature Using Selective GRAntagonism in ER-Negative Breast CancerDiana C. West, Masha Kocherginsky,Eva Y. Tonsing-Carter, D. Nesli Dolcen, David J. Hosfield,Ricardo R. Lastra, Jason P. Sinnwell, Kevin J. Thompson,Kathleen R. Bowie, Ryan V. Harkless, Maxwell N. Skor,Charles F. Pierce, Sarah C. Styke, Caroline R. Kim,Larischa de Wet, Geoffrey L. Greene, Judy C. Boughey,Matthew P. Goetz, Krishna R. Kalari, Liewei Wang,Gini F. Fleming, Bal�azs Gy€orffy, and Suzanne D. Conzen

3447 A Survey on Data Reproducibility and theEffect of Publication Process on the EthicalReporting of Laboratory ResearchDelphine R. Boulbes, Tracy Costello, Keith Baggerly,Fan Fan, Rui Wang, Rajat Bhattacharya, Xiangcang Ye, andLee M. Ellis

3456 Identification and Validation of a 3-GeneMethylation Classifier for HPV-BasedCervical Screening on Self-SamplesWina Verlaat, Barbara C. Snoek, Dani€elle A.M. Heideman,Saskia M. Wilting, Peter J.F. Snijders, Putri W. Novianti,Annina P. van Splunter, Carel F.W. Peeters,Nienke E. van Trommel, Leon F.A.G. Massuger,Ruud L.M. Bekkers, Willem J.G. Melchers,Folkert J. van Kemenade, Johannes Berkhof,Mark A. van de Wiel, Chris J.L.M. Meijer, andRenske D.M. Steenbergen

3465 Mechanistic Insights of an ImmunologicalAdverse Event Induced by an Anti-KIT AntibodyDrug Conjugate and Mitigation StrategiesLawrence L'Italien, Olivia Orozco, Tinya Abrams,Lisa Cantagallo, Anu Connor, Jayesh Desai,Hilmar Ebersbach, Hans Gelderblom, Keith Hoffmaster,Emma Lees, Heiko Maacke, Siew Schleyer, Darko Skegro,and Si Tuen Lee-Hoeflich

AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows an ovarian cancer tissue section from a patient harboring a rare PD-L1tumor genetic rearrangement. Immunofluorescence multiplex imaging demonstratesstrong colocalization of PD-L1 and cytokeratin in the tumor cells with negative PD-L1expression in infiltrating CD68þ macrophages. PD-L1 (red)/cytokeratin (green)/DAPI(blue)/CD68 (magenta). For details, see the article by Bellone and colleagues on page 3282of this issue.

Table of Contents

vi

on May 6, 2019. © 2018 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from

2018;24:3231-3474. Clin Cancer Res     24 (14)

  Updated version

  http://clincancerres.aacrjournals.org/content/24/14

Access the most recent version of this article at:

   

   

   

  E-mail alerts related to this article or journal.Sign up to receive free email-alerts

  Subscriptions

Reprints and

  .pubs@aacr.org

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at

  Permissions

  Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)

.http://clincancerres.aacrjournals.org/content/24/14To request permission to re-use all or part of this article, use this link

on May 6, 2019. © 2018 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from